curasan AG Receives License for Ceracell® Dental in the USA
curasan AG has received FDA certification for its new granular bone regeneration material Ceracell® Dental
Kleinostheim, Germany, May 07, 2011 --(PR.com)-- curasan AG, listed in the General Standard of the German Stock Exchange has received FDA certification for its new granular bone regeneration material Ceracell® Dental.
Ceracell® is a synthetic, completely absorbable and bioactive bone regeneration material. Although the porosity compared to Cerasorb® has been increased considerably yet again, the material has greater mechanical stability. Thanks to the spongy structure designed after human bones and an optimised formulation an increased number of bone-forming cells dock on Ceracell®, which leads to accelerated and qualitatively better bone regeneration.
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading companies in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. Some of these various new developments are ready yet for market rollout. These biomaterials will be marketed globally by well-positioned contractual partners. Further products will follow until end of 2012. www.curasan.com
###
Ceracell® is a synthetic, completely absorbable and bioactive bone regeneration material. Although the porosity compared to Cerasorb® has been increased considerably yet again, the material has greater mechanical stability. Thanks to the spongy structure designed after human bones and an optimised formulation an increased number of bone-forming cells dock on Ceracell®, which leads to accelerated and qualitatively better bone regeneration.
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading companies in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. Some of these various new developments are ready yet for market rollout. These biomaterials will be marketed globally by well-positioned contractual partners. Further products will follow until end of 2012. www.curasan.com
###
Contact
curasan AG
Andrea Weidner
+49 (0)6027 40 900-51
www.curasan.de
Andrea Weidner
+49 (0)6027 40 900-51
www.curasan.de
Contact
Categories